Intech Investment Management LLC Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Intech Investment Management LLC purchased a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 52,953 shares of the company’s stock, valued at approximately $349,000.

Other hedge funds have also made changes to their positions in the company. Allspring Global Investments Holdings LLC acquired a new stake in shares of Recursion Pharmaceuticals during the third quarter worth $25,000. Farther Finance Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after purchasing an additional 4,091 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares during the last quarter. KBC Group NV boosted its holdings in shares of Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares during the last quarter. Finally, Amalgamated Bank boosted its holdings in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Down 6.5 %

Shares of Recursion Pharmaceuticals stock opened at $7.09 on Wednesday. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market cap of $2.03 billion, a P/E ratio of -4.63 and a beta of 0.85. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $5.60 and a fifty-two week high of $15.74. The business has a 50-day moving average price of $6.59 and a 200 day moving average price of $7.37.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. During the same period in the prior year, the firm earned ($0.43) earnings per share. The firm’s quarterly revenue was up 147.6% compared to the same quarter last year. On average, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total value of $123,200.00. Following the completion of the sale, the chief executive officer now directly owns 762,656 shares in the company, valued at $4,697,960.96. This represents a 2.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 134,235 shares of company stock worth $895,538 over the last ninety days. Company insiders own 15.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, November 20th. Jefferies Financial Group reduced their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Finally, Leerink Partners reduced their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.